Medarex Zusammenarbeit mit ....... - 500 Beiträge pro Seite
eröffnet am 03.04.00 15:21:57 von
neuester Beitrag 05.04.00 12:41:05 von
neuester Beitrag 05.04.00 12:41:05 von
Beiträge: 8
ID: 109.905
ID: 109.905
Aufrufe heute: 0
Gesamt: 795
Gesamt: 795
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 20.04.24, 12:11 | 167 | |
| heute 00:14 | 161 | |
| 05.12.14, 17:15 | 155 | |
| heute 00:04 | 123 | |
| 23.10.15, 12:38 | 116 | |
| gestern 09:54 | 103 | |
| gestern 21:21 | 92 | |
| 06.03.17, 11:10 | 75 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.161,01 | +1,36 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3500 | +1,14 | 60 | |||
| 5. | 4. | 168,29 | -1,11 | 50 | |||
| 6. | Neu! | 0,4400 | +3,53 | 36 | |||
| 7. | Neu! | 4,7950 | +6,91 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 31 |
Feedback
Hallo Freunde von Medarex.....
Wusste Förtsch schon das neueste am Sonntag?
Neueste Meldung aus USACollaboration Agreement
BusinessWire
Monday April 3 7:09am
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 3, 2000-- Coulter Pharmaceutical (Nasdaq:CLTR) and Medarex, Inc. (Nasdaq:MEDX) today announced a collaboration through which Coulter will obtain access to Medarex`s HuMAb-Mouse(TM) technology to generate fully human monoclonal antibodies against a number of specific target antigens.
Under the terms of the agreement, Coulter will have the option to obtain exclusive commercial rights to these antibodies. In return, Medarex could receive research and development payments, license fees and milestone payments, as well as royalties on commercial sales of the fully human antibodies developed by Coulter.
"Coulter`s access to Medarex`s technology represents a significant expansion of our therapeutic antibody program," said Michael F. Bigham, Coulter`s president and chief executive officer. "This technology will enable us to rapidly develop antibodies against our select targets for cancer and autoimmune diseases."
"Coulter is our eighteenth corporate partner for our HuMAb-Mouse technology to create novel human antibodies," said Donald L. Drakeman, president and CEO of Medarex. "We are very pleased with Coulter`s validation of the power of our technology to generate antibodies for the treatment of cancer and autoimmune diseases."
Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics.
The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. The company`s therapeutic antibody program includes an antibody-based approach to block the Type I interferon receptor for the treatment of autoimmune diseases and transplant rejection.
Initial efforts in the targeted oncologics program are focused on the development of a tumor-activated pro-drug version of doxorubicin to potentially treat certain solid tumor cancers. For more company information, visit Coulter Pharmaceutical`s web site at www.coulterpharm.com.
Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. The company has developed a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse system for the creation of high affinity human antibodies.
Medarex`s HuMAb-Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Medarex creates and develops human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about the company, visit its site at www.medarex.com.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance the companies` product candidates, uncertainties related to business opportunities, the receipt of future payments, the continuation of business partnerships and other risks detailed from time to time in the companies` filings with the Securities and Exchange Commission (SEC).
Contact: Coulter Pharmaceutical, Inc., South San Francisco
Sylvia Wheeler, 650/553-2000
or
Medarex, Inc., Princeton, N.J.
Donald L. Drakeman, 609/430-2890
or
Middleberg + Associates
Kimberly Hofman, 212/888-6610 ext. 544
Wusste Förtsch schon das neueste am Sonntag?
Neueste Meldung aus USACollaboration Agreement
BusinessWire
Monday April 3 7:09am
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 3, 2000-- Coulter Pharmaceutical (Nasdaq:CLTR) and Medarex, Inc. (Nasdaq:MEDX) today announced a collaboration through which Coulter will obtain access to Medarex`s HuMAb-Mouse(TM) technology to generate fully human monoclonal antibodies against a number of specific target antigens.
Under the terms of the agreement, Coulter will have the option to obtain exclusive commercial rights to these antibodies. In return, Medarex could receive research and development payments, license fees and milestone payments, as well as royalties on commercial sales of the fully human antibodies developed by Coulter.
"Coulter`s access to Medarex`s technology represents a significant expansion of our therapeutic antibody program," said Michael F. Bigham, Coulter`s president and chief executive officer. "This technology will enable us to rapidly develop antibodies against our select targets for cancer and autoimmune diseases."
"Coulter is our eighteenth corporate partner for our HuMAb-Mouse technology to create novel human antibodies," said Donald L. Drakeman, president and CEO of Medarex. "We are very pleased with Coulter`s validation of the power of our technology to generate antibodies for the treatment of cancer and autoimmune diseases."
Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics.
The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. The company`s therapeutic antibody program includes an antibody-based approach to block the Type I interferon receptor for the treatment of autoimmune diseases and transplant rejection.
Initial efforts in the targeted oncologics program are focused on the development of a tumor-activated pro-drug version of doxorubicin to potentially treat certain solid tumor cancers. For more company information, visit Coulter Pharmaceutical`s web site at www.coulterpharm.com.
Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. The company has developed a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse system for the creation of high affinity human antibodies.
Medarex`s HuMAb-Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Medarex creates and develops human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about the company, visit its site at www.medarex.com.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance the companies` product candidates, uncertainties related to business opportunities, the receipt of future payments, the continuation of business partnerships and other risks detailed from time to time in the companies` filings with the Securities and Exchange Commission (SEC).
Contact: Coulter Pharmaceutical, Inc., South San Francisco
Sylvia Wheeler, 650/553-2000
or
Medarex, Inc., Princeton, N.J.
Donald L. Drakeman, 609/430-2890
or
Middleberg + Associates
Kimberly Hofman, 212/888-6610 ext. 544
Vorsicht Leute wird nicht gut aufgenommen,
- 11 % Stand 44,..€
Immos
- 11 % Stand 44,..€
Immos
Medarex hat gedreht + 3 % !!
was hat hier jemand zu suchen, der euro und dollar nicht auseinanderhalten kann ??? ...
(nicht böse sein Immos)
(nicht böse sein Immos)
Hallo Leute bin nicht böse sondern wohl nur übermüdet (tipfehler)
aber was da abgeht ist echt geil,
das ist wie der Sprung am Gummiseil.
das macht solangsam richtig spaß und ist natürlich meine spannendste Investition.
freue mich schon richtig auf morgen
Prognosen wären zwar ein lesen im Kaffeesatz aber ich tippe bei uns auf 59-60
Toll !!!!!
Bis morgen IMMOS
aber was da abgeht ist echt geil,
das ist wie der Sprung am Gummiseil.
das macht solangsam richtig spaß und ist natürlich meine spannendste Investition.
freue mich schon richtig auf morgen
Prognosen wären zwar ein lesen im Kaffeesatz aber ich tippe bei uns auf 59-60
Toll !!!!!
Bis morgen IMMOS
Trading Spotlight
Hallo Immos !!
schön auf dem Boden bleiben mehr als 58€ sind morgen bei uns noch nicht drin dennoch geht`s wieder aufwärts !!
Gute Nacht alle bis morgen !!
Bioracer
schön auf dem Boden bleiben mehr als 58€ sind morgen bei uns noch nicht drin dennoch geht`s wieder aufwärts !!
Gute Nacht alle bis morgen !!
Bioracer
Ich denke medarex wird in den nächsten Wochen noch sehr gut performen. Wer sich die Internet-Homepage von medarex.com anschaut, wird schnell realisieren, wieviel Potenzial hier noch steckt.
Kann ich Dir nur Recht geben!
Die ganzen skeptiker, die immer davon reden wo Medarex herkommt
sollten sich mal gedanken machenwarum sie an der Börse investieren!!
Sicherlich nicht um immer skeptisch zurück zu blicken oder??
Ich bin der Meinung € 200 war vielleicht ein wenig übertrieben oK,
aber wir werden sicher noch freude an diesem Wert haben!!!
schitt
Die ganzen skeptiker, die immer davon reden wo Medarex herkommt
sollten sich mal gedanken machenwarum sie an der Börse investieren!!
Sicherlich nicht um immer skeptisch zurück zu blicken oder??
Ich bin der Meinung € 200 war vielleicht ein wenig übertrieben oK,
aber wir werden sicher noch freude an diesem Wert haben!!!
schitt
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 90 | ||
| 78 | ||
| 58 | ||
| 55 | ||
| 35 | ||
| 34 | ||
| 29 | ||
| 26 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 21 | ||
| 19 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
